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Reduced plasma concentration of 1,25.dihydroxyvitamin D in children
with moderate renal insufficiency. We measured the plasma concentra-
tion of 1 ,25-dihydroxyvitamin D (I ,25-(OH)2D) in 39 children compris-
ing three groups: eight with moderate renal insufficiency (GFR of 25 to
50 mI/mm/I .73M2, seven of whom had tubulointerstitial disease), eight
with severe renal insufficiency (on chronic hemodialysis), and 23
healthy control subjects. The mean plasma concentration of 1,25-
(OH)2D was reduced by some 40% (P < 0.002) in the children with
moderate renal insufficiency, and by some 80% (P < 0.001) in the
children with severe renal insufficiency. In the children with moderate
renal insufficiency, the reduced concentration of 1 ,25-(OH)2D was
associated with increased serum concentrations of immunoreactive
parathyroid hormone (iPTH) and reduced serum concentrations of
calcium and phosphorus. When analyzed over the range of renal
function from normal through severely impaired, values of iPTH
correlate inversely and significantly with those of I ,25-(OH)2D. Growth
was impaired in four of the eight children with moderate renal insuffi-
ciency. The results of the current study suggest that in children with
moderate renal insufficiency, a reduction in the renal synthesis and in
the plasma concentration of I ,25-(OH)2D may be important pathogenet-
ic events in disordered metabolism of calcium and phosphorus, includ-
ing secondary hyperparathyroidism.
Diminution de Ia concentration plasmatique de 1,25-dihydroxyvitamine
D chez des enfants ayant une insuffisance renale moderee. Nous avons
mesuré Ia concentration plasmatique de I ,25-dihydroxyvitamine D
(l,25-(OH)2D) chez 39 enfants répartis en trois groupes: 8 avaient une
insuffisance rénale modérée (GFR de 25 a so mI/mn/I .73m2 sept d'entre
eux ayant une néphropathie tubulo-interstitielle), huit ayant une insuffi-
sance rénale sévère (en hémodialyse chronique), et 23 sujets contrôles
sains. La concentration plasmatique moyenne de I ,25-(OH)2D était
diminuée de 40% (P < 0.002) chez les enfants ayant une insuffisance
rénale modérée, et de 80% (P < 0.001) chez les enfants ayant une
insuffisance rénale sévère. Chez les enfants ayant une insuffisance
rénale modérée, La diminution de Ia concentration de 1 ,25-(OH)2D était
associée avec une augmentation des concentrations sériques d'hormone
parathyroidienne immunoréactive (iPTH), et avec des concentrations
diminuées de calcium et de phosphore. Lorsque les résultats étaient
étudiés scion Ia fonction rénale, les valeurs de iPTH étaient inverse-
ment Ct significativement corrélées avec celles de Ia l,25-(OH)2D. La
croissance était ralentie chez quatre des enfants ayant une insuffisance
rénale modérée. Les résultats de cette étude suggèrent que chez les
enfants ayant une insuffisance rénale modérée, une diminution de Ia
synthese rénale et de Ia concentration plasmatique de l,25-(OH)2D
pourrait avoir un role important dans Ia génese des anomalies du
métabolisme du calcium et du phosphore et de l'hyperparathyroIdisme
secondaire.
(OH)2D3 from its endogenous precursor, 25-hydroxyvitamin
D3, occurs in the renal cortex [5—7]. In anephric patients, 1,25-
(OH)2D cannot be detected in plasma [8, 9]. In patients with
severe renal insufficiency, the severe reduction in plasma
concentration of I ,25-(OH)2D [8—10] presumably reflects its
greatly reduced renal synthesis. Accordingly, in patients with
moderate renal insufficiency, a reduction in renal synthesis and
plasma concentration of 1 ,25-(OH)2D might be important patho-
genetic events in the occurrence of hypocalcemia and second-
ary hyperparathyroidism [11—13], impaired calcemic response
to parathyroid hormone [14, 15], reduced intestinal absorption
of calcium [16], and defective mineralization of bone [17]. Yet,
in a preliminary report of adult patients with moderate renal
insufficiency (mean GFR, 50 mI/mm), the mean serum concen-
tration of l,25-(OH)2D was not reduced [18].
In children, the metabolism of vitamin D is quantitatively
different from that of adult subjects, at least with respect to
1,25-(OH)2D: The serum concentration of l,25-(OH)2D in nor-
mal children is higher than that in normal adult subjects [10, 19,
20], findings that could reflect the special metabolic circum-
stance of normal somatic growth. In children with severe renal
insufficiency, growth is characteristically impaired [21—23], and
the incidence of osteodystrophy is higher than in adult patients
with severely reduced renal function [24]. Children with even
moderate renal insufficiency are often growth retarded [22, 23].
In our study of children with moderate renal insufficiency, we
find that the mean plasma concentration of l,25-(OH)2D is
significantly reduced; this reduction might be an important
pathogenetic determinant of impaired intestinal absorption of
calcium, hypocalcemia, and secondary hyperparathyroidism.
Methods
Subjects. We measured the plasma concentration of 1,25-
(OH)2D in 39 children comprising three groups: eight children
aged 3 to 13 years with moderate renal insufficiency (defined as
GFR of 25 to 50 ml/min/l.73M2), eight children aged 7 to 18
years with severe renal insufficiency (on chronic hemodialysis),
and 23 healthy control subjects (serum concentration of creati-
The metabolite of vitamin D, 1,25-dihydroxyvitamin D3 (1,25-
(OH)2D3), is currently considered to be the most biologically
active with respect to bone resorption and intestinal absorption
of calcium and of phosphorus [1—4]. The synthesis of 1,25-
627
Received for publication May IS, 1981
and in revised form October 27, 1981
0085—2538/82/0021—0627 $01.20
© 1982 by the International Society of Nephrology
628 Portale et al
Table 1. Clinical and biochemical characteristics of children with moderate renal insufficiency
Age Heighta GFR
Plasma
l,25-(OH)2D
Serum
iPTH Ca p
Patient no. years so Disease mi/min/1.73M2 pg/mi i.i eq/mi mg/di
1 6.8 0.8 Hemolytic uremic syndrome 50 34 59 10,1 3.9
2 13.4 2.6 Medullary cystic disease 50 27 270 9.2 4.8
3 9.7 3.5 Bilateral hydronephrosis 48b 42 38 9.7 3.9
4 5.6 0 Interstitial nephritis 43 44 36 9.3 4.1
5 9.3 0.2 Congenital dysplasia; hydronephrosis 42 24 50 9.9 3.2
6 11.1 2.5 Posterior urethral valves 42 16 55 9.4 4.3
7 11.2 1.0 Interstitial nephritis 35 29 110 9.0 4.1
8 3.5 2.3 Congenital dysplasia 28 42 270 9.3 5.8
Patients
Mean SEM 42 3 32 4 111 36 9.5 0.1c 4.3 0.3"
Controls
Range 127a
(89—165)
54 4
(31—115)
17 2
(5—34)
10.1 0.1 4.8 0.1
(9.4—10.8) (4.0—5.6)
a Height is expressed as SD below the mean for chronological age.
b GFR is estimated by creatinine clearance; in all the other children, GFR estimated by iothalamate clearance.
Value vs controls, P < 0.001; "vs controls, P < 0.005.
Normal values in children aged 3 to 12 years, obtained by measurement of inulin clearance [48, 49].
Abbreviations are GFR, glomerular filtration rate; 1 ,25-(OH)2D, I ,25-dihydroxyvitamin D; iPTH, immunoreactive parathyroid hormone; Ca,
calcium; P, phosphorus.
nine 0.2 to 0.8 mg/dl) aged 3 to 15 years. In 20 of these control
subjects and in 11 additional healthy children, we measured
serum concentrations of calcium, phosphorus, immunoreactive
parathyroid hormone (iPTH), alkaline phosphatase, total pro-
tein, and albumin on blood drawn in the morning.
Seven of the eight children with moderate renal insufficiency
had tubulointerstitial renal disease, and one child had glomeru-
lar disease (Table 1). These children had not received phos-
phate binding agents, calcium supplements, vitamin D, or any
of its analogs. Six of the eight children were studied in the
Pediatric Clinical Research Center and received a fixed normal
dietary intake of calcium (800 mg per day) and phosphorus
(1000 mg per day) for 5 days; the two other children were
studied as outpatients. Blood was drawn in the morning fasting
state for measurement of serum concentrations of calcium,
phosphorus, iPTH, and plasma concentrations of 1 ,25-(OH)2D.
GFR, estimated by clearance of iothalamate in seven children
and by endogenous creatinine clearance in one, ranged from 28
to 50 ml/min!l.73M2, the mean being 42. In the six children
studied under fixed metabolic conditions, urinary excretion of
calcium and phosphorus was determined from three successive
24-hr balance periods; values were compared with those ob-
tained by Macy [25] in metabolic balance studies of 9 healthy
children aged 5 to 12 years whose dietary intake of calcium,
phosphorus, and protein closely approximated that of the
currently studied children. In five of the six children, serum
concentrations of calcium, phosphorus, and iPTH were mea-
sured in the fasting state and 2 hr alter each of the three meals.
The children with severe renal insufficiency were receiving oral
calcium carbonate and aluminum hydroxide when studied but
had not received supplements of vitamin D or any of its analogs
for the prior period of 4 weeks. These studies were performed
under a protocol approved for use by the Committee on Human
Research, University of California, San Francisco. Informed
consent was obtained from the parents of all children studied.
1,25-(OH)2D assay. Plasma concentrations of 1 ,25-(OH)2D
were measured using a competitive protein binding assay
modified from that of Eisman et al [9]. Five milliliters of plasma
were subjected to lipid extraction with methanol and dichloro-
methane (2:1); a known amount of tritiated 1 ,25-(OH)2D3 was
added to the plasma to determine percent recovery. The
fraction containing 1 ,25-(OH)2D was separated from other
plasma lipids by Sephadex LH 20 column chromatography
using hexane: chloroform: methanol (9: 1: 1), and was further
purified by high-pressure liquid chromatography using a p-
porasil column in 10% isopropanol in hexane. The amount of
l,25-(OH)2D in the sample was determined by its displacement
of tritiated 1 ,25-(OH)2D3 from intestinal cytosol obtained from
vitamin D-deficient chicks. The lower limit of detection of 1,25-
(OH)2D is 5 pglml. Overall recovery of l,25-(OH)2D was 62
2% (mean SEM, N = 32). Intra-assay coefficient of variation
was 13%. In normal adult subjects, the plasma concentration of
l,25-(OH)2D was 37 pg/ml (mean SEM, N = 15); this value
agrees closely with values reported in other adult subjects [8, 9,
26, 27].
Serum concentrations of iPTH were measured by radio-
immunoassay in the laboratory of Dr. Sara Arnaud using an
antiserum (GP-IM) with affinity for the hormone's C-terminal
[28]. Serum and urinary concentrations of calcium were mea-
sured by atomic absorption spectrophotometry, serum concen-
trations of phosphorus by a modification of the Fiske-Subbarow
method [29], and urinary phosphorus by Auto-Analyzer. The
Mann-Whitney test was used for statistical comparison of
differences between values of 1 ,25-(OH)2D in the three groups
of children, as the values in the control group are not normally
distributed. The unpaired Student's t test was used for all other
group comparisons. Correlation coefficients were calculated by
Spearman's rank correlation procedure.
Results
In the 23 healthy children, the mean plasma concentration of
1 ,25-(OH)2D was 54 4 pg/mI, a value significantly higher than
that in normal adult subjects (P < 0.005). This value in normal
children is in agreement with that reported by Lund et al [20] in
_ It1
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Fig. 1. Plasma Concentrations of 1,25-dihydroxyvitamin D. The mean
values in the children with moderate and severe renal insufficiency are
reduced (P < 0.002 and P < 0.001, respectively).
a control group of children aged 4 to 14 years but is somewhat
higher than that reported by Chesney et al 1101.
In the children with moderate renal insufficiency, the plasma
concentration of l,25-(OH)2D was 32 4 pg/ml, a value
significantly lower than that in the normal children (P < 0.002)
(Table 1, Fig. 1). The values of l,25-(OH)2D in six of the eight
children with moderate renal insufficiency were less than the
lowest value observed in normal children matched for age,
while the values in the two other children were within the
normal range of values (Fig. 2). In the children with severe renal
insufficiency, the plasma concentration of 1,25-(OH)2D was 10
2 pg/mI, a value greatly reduced relative both to that in the
normal children and in the children with moderate renal insuffi-
ciency (P <0.001, Fig. 1).
In each child with moderate renal insufficiency, the serum
concentration of iPTH was above the normal range; the mean
value was ill 36 i.l eq/ml (Table 1). In the children with
severe renal insufficiency, the serum concentration of iPTH
was 2080 720 1 eq/mi. Over the range of renal function from
normal through severely impaired, the correlation between
values of iPTH and 1 ,25-(OH)2D was inverse and highly signifi-
cant (r = —0.816, P < 0.001, Fig. 3).
In the children with moderate renal insufficiency, the mean
serum concentrations of both calcium and phosphorus were
significantly reduced (Table 1). In four children, serum concen-
trations of calcium were below the normal range, and in three,
serum concentrations of phosphorus were below the normal
range. In the five children in whom the measurements were
made, the mean serum concentration of phosphorus was re-
duced in the morning fasting state and did not increase signifi-
cantly after any of the three meals (Fig. 4). Similarly, the serum
concentrations of both calcium (not shown) and iPTH did not
change significantly in the postprandial period although the
value of iPTH appeared to trend upward from 3 to 8 P.M. In the
children on hemodialysis, the serum concentration of calcium
was reduced (9.2 0.4 mg/dl, P < 0.002); the serum concentra-
tion of phosphorus was not increased (4.6 0.7 mg/dl), and
neither of these values was different from those of the children
with moderate renal insufficiency. Mean serum concentrations
of total protein and albumin in the patient groups were not
different from those in the control group.
In the six children with moderate renal insufficiency studied
under fixed metabolic conditions, the daily urinary excretion of
both calcium and phosphorus was significantly reduced relative
to values in normal children on similar dietary intake of calcium
and phosphorus (Table 2). The fractional excretion of phospho-
rus in the six children studied was 31 1%; the reported range
in normal children is 7 to 16% 1301.
The mean venous total carbon dioxide content was 23 1
mEq/liter in the eight children with moderate renal insufficien-
cy. Values of total carbon dioxide content did not correlate with
those of plasma 1 ,25-(OH)2D.
In the children with moderate renal insufficiency, bone age
was retarded by a mean of 1.7 SD. In three children, mild
subperiosteal resorption was present, as judged from finely
detailed radiographs of the hand. The mean serum concentra-
tion of alkaline phosphatase in the eight children was greater
than that in the controls (239 41 vs. 125 8 lU/liter, P <
0.001).
In four of the eight children, height was more than 2 SD below
the mean of age-matched normal children (National Center for
Health Statistics); the mean reduction for the group of eight was
1.6 SD (Table 1). Over a period of 12 to 15 months, three of the
children with short stature grew at a reduced velocity and
became further growth retarded; the growth velocity of the
other five children remained normal. Reduction of neither the
height nor the growth velocity correlated with the values of
plasma 1 ,25-(OH)2D, serum iPTH, or GFR.
Discussion
Our study demonstrates that in children in whom GFR is
moderately reduced (to 25 to 50 ml/min/l.73M2), the mean
plasma concentration of 1,25-(OH)2D is reduced by some 40%.
In seven of the eight children studied, renal insufficiency was
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Fig. 3. The relationship between concentrations of iPTH and 1,25-
(OH)2D over the entire range of rena/function, from normal (controls)
to moderate and severe impairment. The correlation is inverse and
significant (r = —0.816, P < 0.001).
caused by disease that principally affects the renal tubulointer-
stitium. The findings in these children might then be different
from those in children with disease that principally affects the
glomerulus. Yet, in two children with chronic glomerulonephri-
tis in whom GFR ranged from 30 to 40 ml/min/l.73M2 [10] (as
estimated from height and serum creatinine [311), the serum
concentrations of l,25-(OH)2D (19 and 30 pg/mI) were reduced.
In the children with severe renal insufficiency on hemodialysis,
the plasma concentration of l,25-(OH)2D of 10 2 pg/ml
constitutes a reduction of some 80% and accords with the value
of 13 5 pg/ml reported in children with severe renal insuffi-
ciency not on dialysis and with renal osteodystrophy [10].
In children with moderate renal insufficiency whom we studied,
the reduced plasma concentration of 1 ,25-(OH)2D was associated
with hyperparathyroidism and reduced serum concentrations of
calcium and phosphorus. The reduced circulating level of 1,25-
(OH)2D, by reducing intestinal absorption of calcium [2, 3] and by
impairing the calcemic response to endogenous parathyroid
hormone [32], could have been an important pathogenetic
determinant of the reduction in serum calcium and thereby of
secondary hyperparathyroidism. Consistent with this formula-
tion is our observation that circulating levels of iPTH correlated
inversely and significantly with those of 1 ,25-(OH)2D over the
range of renal function from normal to severely impaired. A
decrease in intestinal absorption of calcium in the children with
moderate renal insufficiency is suggested by the finding that
their urinary excretion of calcium was greatly reduced. In adult
patients with renal insufficiency studied by Malluche, Werner,
and Ritz [16], intestinal absorption of calcium was reduced in
half of those patients in whom the values of GFR were 30 to 40
ml/min/1 .73M2. The increased circulating levels of iPTH in
patients we studied might reflect not only increased secretion of
parathyroid hormone but also reduced renal clearance of its C-
terminal fragments [33].
According to the formulation of Slatopolsky et al, phosphate
retention plays the major pathogenetic role in the secondary
hyperparathyroidism of chronic renal failure [34—36]. In chil-
dren we studied who had moderate renal insufficiency, cvi-
dence of phosphate retention could not be demonstrated: In
seven of the eight children, the morning fasting serum concen-
tration of phosphorus was less than the mean value in normal
children of similar age, and in three children the value was
frankly reduced. Reduced morning serum concentrations of
phosphorus have also been reported in adult patients with
moderate renal insufficiency [11, 15]. In such patients, it has
been suggested that morning fasting hypophosphatemia might
reflect continuing hyperparathyroidism evoked by earlier post-
prandial hyperphosphatemia [36]. Indeed, in the phosphate-
loaded normal dog [36, 37], fasting hypophosphatemia can be
causally related to continuing hyperparathyroidism evoked and
transiently enhanced by postprandial hyperphosphatemia that
persists for approximately 8 hr. But, in the five children we
studied in whom the measurements were made, the serum
concentrations of phosphorus and of iPTH did not increase in
the postprandial period. In adult patients with moderate renal
insufficiency, the serum concentration of phosphorus exceeded
that of control subjects only after an oral load of phosphorus (1
g) doubled their otherwise normal daily dietary intakes of
phosphorus (0.8 to 1 g) [38].
In three of the eight children we studied who had moderate
renal insufficiency, mild subperiosteal resorption was radio-
graphically demonstrable. Norman et al [39] found histologic
evidence of osteomalacia, hyperparathyroidism, or both in each
of 24 children in whom the values of GFR were less than 45
ml/min/l.73M2, even though radiographs and serum levels of
calcium, phosphorus, and alkaline phosphatase were judged to
be normal in approximately one fourth of the children. In four
of the eight children in this study, height was reduced by more
than 2 SD, and in three growth velocity was reduced. In children
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Table 2. Dietary intake and urinary excretion of caicium and phosphorus in children with moderate renat insufficiency
Subjects (N) Age
years
Dietary intake Urinary excretion
Calcium Phosphorous
mg/kg/day
Calcium Phosphorus
mg/kg/day
Controls" (9)
Patients (6)
8.7 0.8
9.6 1.2
30 2
35 5
44 2
41 4
4.0 0.4
0.5 0.1'
27.0 1.1
9.1 l.9d
a Values are means 5EM; N refers to the number of children in the study.
"Values derived from data of Macy [251.
Patient data vs. controls, P < 0.001.
d Patient data vs. controls, P < 0.002.
with severe renal insufficiency and short stature, growth veloci-
ty has been reported to increase when 1,25-(OH)2D3 was
administered [40, 41].
In patients with moderate, or even severe, renal insufficien-
cy, the determinants of the presumed reduction in synthesis of
l,25-(OH)2D have not been defined. Twenty-five-hydroxyvita-
mm D- 1 -hydroxylase (la-hydroxylase), the mitochondrial en-
zyme which catalyzes the synthesis of l,25-(OH)2D3, presum-
ably occurs principally in cells of the proximal renal tubule [42,
43]. Renal disease that results in reduction in mass of, or injury
to, the proximal tubule, could reduce the quantity of the
enzyme. In the experimental animal with intact renal function,
an increase in the serum concentration of inorganic phosphorus
has been attended by reduced activity of lc-hydroxylase [44,
45], and by a reduction in plasma concentration of l,25-(OH)2D
[46]. In normophosphatemic patients with moderate renal insuf-
ficiency, an increase in intracellular concentration of phospho-
rus in the proximal tubule of the remaining functioning neph-
rons might reduce the activity of lct-hydroxylase and the
synthesis of l,25-(OH)2D. Consistent with this possibility are
the findings of Llach et al [47]. They observed that in normo-
phosphatemic patients with moderate renal insufficiency, phos-
phate restriction was associated with an improvement in intesti-
nal absorption of calcium, in calcemic response to parathyroid
extract, and in bone histology, as well as a reversal of hyper-
parathyroidism, with no measured change in the serum concen-
tration of phosphorus or net external balance of phosphorus.
Whatever its cause, the reduction in plasma concentration of
1 ,25-(OH)2D in children with moderate renal insufficiency could
well reflect a clinically important disorder of vitamin D metabo-
lism.
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